New drug DXC014 enters first human tests for tough cancers

NCT ID NCT07177937

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times

Summary

This study is testing a new drug called DXC014 in people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check the drug's safety, find the best dose, and see if it can help shrink tumors. About 150 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hunan Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, 410000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University First Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100034, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.